ライフサイエンスコーパス: schistosomiasis

1 is), ulcer care (leprosy), or renal support (schistosomiasis).

2 nalyses of human biopsies from patients with schistosomiasis.

3 There is currently no vaccine against schistosomiasis.

4 aneous leishmaniasis but beneficial in acute schistosomiasis.

5 ontribute to developing new vaccines against schistosomiasis.

6 er from severe morbidity as a consequence of schistosomiasis.

7 ta from the national surveillance system for schistosomiasis.

8 ex life cycle of the parasites causing human schistosomiasis.

9 nt a new risk factor for PAH associated with schistosomiasis.

10 ffective vaccines and chemotherapies against schistosomiasis.

11 redators of the snail intermediate hosts for schistosomiasis.

12 treating the bladder sequelae of urogenital schistosomiasis.

13 at macrophages prevent death from urogenital schistosomiasis.

14 he repurposing or discovery of drugs against schistosomiasis.

15 for development of new strategies to control schistosomiasis.

16 ing targets for blocking the transmission of schistosomiasis.

17 contribution to controlling, or eliminating, schistosomiasis.

18 y the pulmonary vascular response to chronic schistosomiasis.

19 cts for the development of a vaccine against schistosomiasis.

20 to the increased regulatory milieu found in schistosomiasis.

21 infections, including the helminthic disease schistosomiasis.

22 ssion model might overestimate human risk of schistosomiasis.

23 Bregs) on T-cell cytokines in vitro in human schistosomiasis.

24 ium worms, the etiologic agent of urogenital schistosomiasis.

25 may be involved in the pathogenesis of human schistosomiasis.

26 ection to mass drug administration (MDA) for schistosomiasis.

27 at MBL is also associated with protection in schistosomiasis.

28 etwork of host-parasite relationships during schistosomiasis.

29 2 serum levels as protective factors against schistosomiasis.

30 These responses are tightly regulated during schistosomiasis.

31 y and MBL2 polymorphisms are associated with schistosomiasis.

32 the hepatic B cell infiltrate during chronic schistosomiasis.

33 subjects (10%) had severe manifestations of schistosomiasis.

34 l-fetal health in pregnancies complicated by schistosomiasis.

35 gy during the TH1 phase and chronic phase of schistosomiasis.

36 a public health problem (EPHP) as a goal for schistosomiasis.

37 ing on achieving public health goals against schistosomiasis.

38 ple, causing the neglected tropical disease, schistosomiasis.

39 ble for the pathogenesis and transmission of schistosomiasis.

40 d at reducing snail-mediated transmission of schistosomiasis.

41 confirmed non-TB tropical diseases (11 with schistosomiasis, 5 with Chagas' disease, and 10 with cut

42 iciency virus (HIV)/AIDS (7%), malaria (7%), schistosomiasis (6%), and strongyloidiasis (5%); 5% were

43 Schistosomiasis, a chronic helminth infection, elicits d

44 One of the most impactful is schistosomiasis, a disease caused by parasitic blood flu

45 mansoni is one of the etiological agents of schistosomiasis, a key neglected tropical disease respon

46 ke Schistosoma haematobium causes urogenital schistosomiasis, a neglected tropical disease (NTD) that

47 istosomes are parasitic flatworms that cause schistosomiasis, a neglected tropical disease affecting

48 changes are occurring in the epidemiology of schistosomiasis, a neglected tropical disease caused by

49 tic drug praziquantel (PZQ) is used to treat schistosomiasis, a neglected tropical disease that affec

50 Over 250 million people suffer from schistosomiasis, a tropical disease caused by parasitic

51 a haematobium, is the most prevalent form of schistosomiasis affecting humans, and can result in seve

52 Schistosomiasis affects approximately 40 million women o

53 Schistosomiasis affects more than 200 million individual

54 Schistosomiasis affects nearly 40 million women of repro

55 Regional diagnoses included schistosomiasis (Africa) and Chagas disease (Americas).

56 We describe an outbreak of acute schistosomiasis after a brief exposure (mean, 22 +/- 9.5

57 deworming for soil-transmitted helminths or schistosomiasis (alone or in combination with other inte

58 e is the trematode Schistosoma, which causes schistosomiasis, an infectious disease, whose pathology

59 raziquantel (40 mg/kg per treatment) against schistosomiasis and albendazole (400 mg per treatment) a

60 tidae, the parasites responsible for causing schistosomiasis and cercarial dermatitis.

61 s and infertility associated with urogenital schistosomiasis and discuss the basic hormonal mechanism

62 Trematode infections such as schistosomiasis and fascioliasis cause significant morbi

63 loped a transmission model of female genital schistosomiasis and HIV infections that we fit to epidem

64 conomically attractive strategy for reducing schistosomiasis and HIV transmission in sub-Saharan Afri

65 mansoni is the causative agent of intestinal schistosomiasis and infects ~54 million people annually,

66 tal simulation study based on survey data of schistosomiasis and lymphatic filariasis across four cou

67 ew insights into improved treatment for both schistosomiasis and other granulofibrotic diseases.

68 l preventive chemotherapy programmes against schistosomiasis and soil-transmitted helminthiasis are l

69 ntegrated, community-wide MDA programmes for schistosomiasis and soil-transmitted helminthiasis can b

70 hich would have received annual MDA for both schistosomiasis and soil-transmitted helminthiasis under

71 anthelmintic drugs for morbidity control of schistosomiasis and soil-transmitted helminthiasis, whic

72 to address the substantial disease burden of schistosomiasis and soil-transmitted helminthiasis.

73 rapy and complementary interventions against schistosomiasis and soil-transmitted helminthiasis.

74 d preventive chemotherapy programmes against schistosomiasis and soil-transmitted helminthiasis.

75 ed MDA (of praziquantel and albendazole) for schistosomiasis and soil-transmitted helminthiasis.

76 ies is the mainstay of morbidity control for schistosomiasis and soil-transmitted helminths, yet the

77 ed for key pathogenic features of urogenital schistosomiasis and that particular aspects of this sign

78 between the maternal immune responses during schistosomiasis and the progeny's predisposition to alle

79 community-based intervention for preventing schistosomiasis and, consequently, HIV infections in rur

80 Malaria, schistosomiasis, and chronic kidney disease-related anem

81 world, is the causative agent of urogenital schistosomiasis, and is associated with a high incidence

82 asis, malaria, leishmaniasis, toxoplasmosis, schistosomiasis, and paracoccidioidomycosis, in which ho

83 phatic filariasis, trachoma, onchocerciasis, schistosomiasis, and soil-transmitted helminthiasis.

84 No vaccine is available to prevent schistosomiasis, and treatment relies predominantly on t

85 As the WHO treatment guidelines for schistosomiasis are currently under revision, we investi

86 tion from regions where strongyloidiasis and schistosomiasis are endemic to non-endemic countries has

87 Three vaccines against human schistosomiasis are in different phases of clinical deve

88 The worm's eggs, which cause the symptoms of schistosomiasis, are generally used to diagnose the dise

89 granulomas occur, such as leishmaniasis and schistosomiasis, Arg1 plays additional roles such as T-c

90 orld Health Organization's goal to eliminate schistosomiasis as a global health problem by 2025, ther

91 Elimination of schistosomiasis as a public health problem and interrupt

92 rasite vaccine development using malaria and schistosomiasis as examples.

93 Lung tissue from patients with schistosomiasis-associated and connective tissue disease

94 Lung tissue from patients with schistosomiasis-associated and connective tissue disease

95 ing pathways is a useful strategy to prevent schistosomiasis-associated carcinogenesis.

96 Schistosomiasis-associated PAH shares altered vascular T

97 novel therapeutic approach for patients with schistosomiasis-associated PAH.

98 The etiology of schistosomiasis-associated pulmonary arterial hypertensi

99 Lungs of patients with schistosomiasis-associated pulmonary arterial hypertensi

100 ess whether treatment of pregnant women with schistosomiasis at 12-16 weeks gestation leads to improv

101 WHO has published guidelines for control of schistosomiasis based on targeted mass drug administrati

102 hods and Twenty-six returning travelers with schistosomiasis (based on positive results of serologic

103 HIV/AIDS and schistosomiasis both cause a substantial disease burden

104 ry findings resembled those of classic acute schistosomiasis, but the detected eggs were morphologica

105 drug administration (MDA) for the control of schistosomiasis, but they have not been studied during t

106 We modeled urogenital schistosomiasis by injecting the bladder walls of IL-4 r

107 es of the prevalence of strongyloidiasis and schistosomiasis by stool or urine microscopy for larvae

108 k, showing how easily and rapidly urogenital schistosomiasis can be introduced and spread into novel

109 Chronic urogenital schistosomiasis can lead to squamous cell carcinoma of t

110 y can modulate infant immune development and schistosomiasis can occur from early infancy, such that

111 Clinical data have provided evidence that schistosomiasis can promote hepatocellular carcinogenesi

112 ium, the two species responsible for >99% of schistosomiasis cases worldwide.

113 Urogenital schistosomiasis, caused by Schistosoma haematobium, is t

114 Urogenital schistosomiasis, caused by the parasitic trematode Schis

115 Malaria and schistosomiasis coinfections are common, and chronic sch

116 Soil-transmitted helminthiasis and schistosomiasis, considered among the neglected tropical

117 praziquantel (PZQ) is the strategy for human schistosomiasis control aiming to prevent morbidity in l

118 ly endemic, and impact on the feasibility of schistosomiasis control and elimination goals.

119 ts could help develop specific strategies of schistosomiasis control and elimination tailored to the

120 ave important public health implications for schistosomiasis control and programs targeting other neg

121 We tested schistosomiasis control by reintroduced river prawns in

122 their new recommended strategies for global schistosomiasis control emphasizes targeting the freshwa

123 Two groups of baboons (n = 8 each) and a schistosomiasis control group (n = 3) were infected with

124 Despite accelerating progress towards schistosomiasis control in sub-Saharan Africa, several a

125 MDA) with praziquantel is the cornerstone of schistosomiasis control in sub-Saharan Africa.

126 vels and will guide the spatial targeting of schistosomiasis control interventions.

127 Despite great progress on schistosomiasis control over the past 50 years in China,

128 year cross-sectional data from nine national schistosomiasis control programs (in eight countries in

129 rogress and treatment strategies in national schistosomiasis control programs more frequently, with l

130 n important opportunity to guide and monitor schistosomiasis control programs, and that in high-trans

131 DA may pose a threat to the effectiveness of schistosomiasis control programs.

132 ansmission is centrally important in guiding schistosomiasis control programs.

133 become an essential future component of the schistosomiasis control tool box needed to achieve the g

134 d has long-term consequences for sustainable schistosomiasis control.

135 's intermediate hosts may enhance drug-based schistosomiasis control.

136 o make significant headway towards sustained schistosomiasis control.

137 Schistosomiasis currently affects 240 million people wor

138 he development of an effective tool for both schistosomiasis diagnosis and drug delivery.

139 By contrast, hepatointestinal schistosomiasis due to the chronic infection with S. man

140 The impact of urogenital schistosomiasis during pregnancy on birth outcomes and c

141 We have previously shown that schistosomiasis during pregnancy upregulates proinflamma

142 Urogenital schistosomiasis (egg-positive and/or haematuria-positive

143 cipants (35%) were considered to have active schistosomiasis, either due to the detection of parasite

144 With the recent resolution on schistosomiasis elimination by the 65th World Health Ass

145 l diagnostic tools should be incorporated in schistosomiasis elimination programs.

146 erviced by six municipal health centres in a schistosomiasis endemic region of northeastern Leyte, Ph

147 space-time allocation of control measures in schistosomiasis-endemic contexts are discussed.

148 rried out on 693 school-aged children from 5 schistosomiasis-endemic villages in Northern Samar, the

149 At the site of the world's largest recorded schistosomiasis epidemic-the Lower Senegal River Basin i

150 The pathophysiology of female genital schistosomiasis (FGS) is only partially understood.

151 Effective future control of female genital schistosomiasis (FGS) requires an integrated and multise

152 ently, Uganda's crater lakes were considered schistosomiasis free due to their high-altitude location

153 h infrequent mass drug treatment, eliminates schistosomiasis from high-transmission sites.

154 09 to March 2010, the 50 patients with acute schistosomiasis (group 1) bathed in a swimming pool supp

155 tted helminths with or without deworming for schistosomiasis had little effect.

156 Schistosomiasis haematobia also appears to negatively in

157 itological survey was strongly predictive of Schistosomiasis haematobium infection in a nested cohort

158 We evaluate the evidence that early schistosomiasis has adverse effects on birth, growth, an

159 omiasis coinfections are common, and chronic schistosomiasis has been implicated in affecting the sev

160 Treatment of schistosomiasis has relied on a single drug - praziquant

161 time that patients from an outbreak of acute schistosomiasis have been compared to controls.

162 Control strategies to reduce human schistosomiasis have evolved from 'snail picking' campai

163 nal diagnostic tests utilized for urogenital schistosomiasis, highlighting new insights and recent ad

164 and various infectious disorders, including schistosomiasis, HIV, and rheumatic heart disease.

165 Schistosomiasis, however, continues to spread to new geo

166 markers for evaluation of liver pathology in schistosomiasis; however, validation remains to be explo

167 In murine schistosomiasis, immunopathology and cytokine production

168 Schistosoma haematobium and the incidence of schistosomiasis in areas where it is currently endemic,

169 o investigate the epidemiology of urogenital schistosomiasis in Corsica, aiming to elucidate the orig

170 ars to be the case with increased urogenital schistosomiasis in humans around Lake Malawi over recent

171 administration programs and the emergence of schistosomiasis in nontropical areas indicate the need f

172 iduals may provide a new tool for diagnosing schistosomiasis in patients with a low parasite burden.

173 Mozambique had the highest prevalence of schistosomiasis in school-aged children (52.8%, 95% CrI

174 s resident in an area moderately endemic for schistosomiasis in the Philippines.

175 or expanding public health interventions for schistosomiasis in women of reproductive age and prescho

176 ition of the burden and potential effects of schistosomiasis in women of reproductive age and young c

177 Schistosomiasis increases the risk of human immunodefici

178 m, and confirming it as the target of IgE in schistosomiasis infected humans.

179 n, one group was given praziquantel to treat schistosomiasis infection.

180 minth infections, but its role in urogenital schistosomiasis, infection with Schistosoma haematobium

181 Urogenital schistosomiasis, infection with Schistosoma haematobium,

182 Schistosomiasis is a debilitating neglected tropical dis

183 Schistosomiasis is a debilitating parasitic disease infe

184 Schistosomiasis is a debilitating tropical disease cause

185 Schistosomiasis is a major cause of pulmonary arterial h

186 Schistosomiasis is a major global health problem caused

187 Schistosomiasis is a major neglected parasitic disease t

188 Schistosomiasis is a major parasitic disease caused by b

189 Urogenital schistosomiasis is a major public health problem in sub-

190 Urogenital schistosomiasis is a neglected tropical disease caused b

191 Schistosomiasis is a neglected tropical disease that aff

192 Schistosomiasis is a neglected tropical disease that inf

193 Schistosomiasis is a parasitic infection that is widespr

194 Bladder schistosomiasis is a prevalent disease in the developing

195 Schistosomiasis is a severe and chronic disease caused b

196 Schistosomiasis is a snail-borne parasitic disease endem

197 Acute schistosomiasis is a systemic hypersensitivity reaction

198 Schistosomiasis is a water-based, infectious disease wit

199 Schistosomiasis is among the most common parasitic disea

200 Schistosomiasis is among the most prevalent human parasi

201 The bladder pathology of urogenital schistosomiasis is caused by immune responses to eggs de

202 Schistosomiasis is endemic in many low-income and middle

203 the context of humans living in areas where schistosomiasis is endemic.

204 ts migrants from all global regions, whereas schistosomiasis is focused in specific regions and most

205 lable for treatment of the neglected disease Schistosomiasis is Praziquantel, and the possible emerge

206 soni infections, the pathology of urogenital schistosomiasis is related mainly to the egg stage, whic

207 The global burden of schistosomiasis is significant, with fibrosis a major as

208 Schistosomiasis is treated with the drug praziquantel (P

209 Travel-related schistosomiasis is usually associated with prolonged fre

210 d Health Assembly's stated goal to eliminate schistosomiasis, it is time to give snail control anothe

211 onitor the progression of liver pathology in schistosomiasis japonica endemic areas is lacking.

212 Schistosomiasis japonica remains a major public health a

213 . japonicum causes hepatointestinal disease (schistosomiasis japonica) and is challenging to control

214 ting the mitochondrial gene nad1 to diagnose schistosomiasis japonica.

215 s could represent an obstacle to eliminating schistosomiasis japonica.

216 nes, including those for hookworm infection, schistosomiasis, leishmaniasis, and Chagas disease, is b

217 iven liver fibrosis model, the mouse chronic schistosomiasis liver fibrosis model, as well as novel 2

218 opulation associated with protection against schistosomiasis, making hemozoin well placed to play an

219 rgeted to the main human parasitic diseases (schistosomiasis, malaria, trypanosomiasis, leishmaniasis

220 D in distinct or concomitant chronic HCV and schistosomiasis mansoni infections.

221 divided into group-I: patients with chronic schistosomiasis mansoni, group-II: HCV patients without

222 For schistosomiasis, mass deworming might be effective for w

223 By promoting endotoxemia, schistosomiasis may exert additional, maladaptive influe

224 iew of the processes associated with hepatic schistosomiasis may provide new insights into improved t

225 ted to tuberculosis, HBV, Strongyloides, and schistosomiasis, may improve outcomes.

226 sicians did not consider that an epidemic of schistosomiasis might emerge in a nonendemic area.

227 Mass deworming for schistosomiasis might slightly increase weight (0.41 kg,

228 ail populations are critically important for schistosomiasis modeling and control.

229 than 90% of global cases of human intestinal schistosomiasis occur.

230 f 2013, an unexpected outbreak of urogenital schistosomiasis occurred in Corsica, with more than 120

231 Refined estimates of the impact of schistosomiasis on quality of life suggest that it rival

232 pio anubis) to analyze the effect of chronic schistosomiasis on severe malaria.

233 To evaluate the impact of schistosomiasis on trophoblasts of the human placenta, w

234 lmonary arterial hypertension resulting from schistosomiasis, one of the most common causes of pulmon

235 Schistosomiasis, one of the most important neglected tro

236 lidated in the context of drug screening for schistosomiasis, one of the most important NTDs.

237 ted helminths (with or without deworming for schistosomiasis or co-interventions) on growth, educatio

238 Schistosomiasis or snail fever is an endemic parasitic i

239 HO guidelines recommend annual treatment for schistosomiasis or soil-transmitted helminthiasis when p

240 More than 1.5 billion people are affected by schistosomiasis or soil-transmitted helminthiasis.

241 he causative agent of the intestinal form of schistosomiasis (or bilharzia).

242 Human schistosomiasis--or bilharzia--is a parasitic disease ca

243 s B, hepatitis C, malaria, strongyloidiasis, schistosomiasis, other intestinal parasites, syphilis, g

244 rmore our results show the potential risk of schistosomiasis outbreaks in other European areas, warra

245 w tool for the diagnosis and surveillance of schistosomiasis, particularly in low-prevalence and low-

246 In hepatic schistosomiasis, pathology arises when schistosome eggs

247 As schistosomiasis poses a threat to people of all ages, un

248 ew and meta-analysis of strongyloidiasis and schistosomiasis prevalence among migrants born in endemi

249 idemiological data of HIV and female genital schistosomiasis prevalence and coinfection in rural Zimb

250 tematic review to identify surveys including schistosomiasis prevalence data in sub-Saharan Africa vi

251 es the observed spatial patterns of regional schistosomiasis prevalence throughout the country, provi

252 d from a reduction in infected snails, human schistosomiasis prevalence was 18 +/- 5% lower and egg b

253 to potential mechanisms by which urogenital schistosomiasis promotes bladder carcinogenesis.

254 stosoma mansoni, the blood fluke that causes schistosomiasis, ranked among the most prevalent parasit

255 ensity, and prevalence) and human urogenital schistosomiasis reinfection (prevalence and intensity in

256 Treatment of schistosomiasis relies on the drug praziquantel.

257 Schistosomiasis remains a serious public health issue in

258 Maternal schistosomiasis results in upregulation of fibrosis-asso

259 gh-resolution estimation of human urogenital schistosomiasis risk to support targeting of both mass d

260 of the national prevalences of malaria, HIV, schistosomiasis, sanitation, and water-quality indicator

261 s) are implicated in many diseases including schistosomiasis, sarcoidosis and arthritis.

262 Urogenital schistosomiasis, Schistosoma haematobium worm infection,

263 f the three major human pathogens that cause schistosomiasis, Schistosoma japonicum is the only one t

264 Approximately 200,000,000 people have schistosomiasis (schistosome infection).

265 Pooled schistosomiasis seroprevalence was 18.4% (95% CI 13.1-24

266 al neglected tropical diseases (specifically schistosomiasis, soil-transmitted helminths, lymphatic f

267 or soil-transmitted helminthiasis (STH)- and schistosomiasis-specific WASH considerations, and a traf

268 ades of multifaceted control efforts against schistosomiasis, the indirectly transmitted helminth Sch

269 the significant global impact of urogenital schistosomiasis, the mechanisms of bladder granulomogene

270 to transition from control to elimination of schistosomiasis, the need for updated, more sensitive di

271 With the vision of "a world free of schistosomiasis," the World Health Organization (WHO) se

272 mphocytic choriomeningitis virus (LCMV), and schistosomiasis to evade host immunity.

273 y campaigns, just as many people suffer from schistosomiasis today as they did 50 years ago.

274 Schistosomiasis traditionally has been diagnosed by dete

275 f Oncomelania snail density for interrupting schistosomiasis transmission based on the longitudinal d

276 of Oncomelania snail density below which the schistosomiasis transmission cannot be sustained were 0.

277 ents the first application of an integrative schistosomiasis transmission model at a whole-country sc

278 ization recognized that efforts to interrupt schistosomiasis transmission through mass drug administr

279 unity-based MDA has a limited impact in high-schistosomiasis-transmission fishing communities, in the

280 rial (ISRCTN47196031), we randomized 26 high-schistosomiasis-transmission fishing villages in Lake Vi

281 Schistosomiasis treatment induces a profound reduction o

282 iscoveries in the pathogenesis of urogenital schistosomiasis (UGS): (1) comparative genomics, (2) the

283 The capability to diagnose cases of human schistosomiasis using noninvasively collected clinical s

284 In 2016, Science ranked the schistosomiasis vaccine as one of the top 10 vaccines th

285 roduction of an efficacious preventive human schistosomiasis vaccine will require integration into ex

286 alpain, is a leading antigen candidate for a schistosomiasis vaccine.

287 ion article, we focus on salient features of schistosomiasis vaccines in different phases of the clin

288 Annual preventive chemotherapy against schistosomiasis was highly cost-effective in treatment o

289 Urogenital schistosomiasis was not significantly associated with ad

290 Bladder schistosomiasis was suspected after contrast-enhanced co

291 ical consequence of wound healing in chronic schistosomiasis, was exacerbated in Batf3(-/-) mice infe

292 With a focus on children with schistosomiasis, we assess the risk for increased HIV tr

293 lacental compartments in pregnant women with schistosomiasis were 1.3- and 2.4-fold higher, respectiv

294 Risk factors for urogenital schistosomiasis were characterized among 4,437 pregnant

295 animals (mice and rabbits) or patients with schistosomiasis were measured by ELISA.

296 mes are parasitic platyhelminthes that cause schistosomiasis, which is a life-threatening infectious

297 ined the first tractable model of urogenital schistosomiasis with an established mouse model of bacte

298 We combined a mouse model of urogenital schistosomiasis with macrophage-depleting liposomal clod

299 cellular and molecular mechanisms of hepatic schistosomiasis, with an emphasis on the major cellular

300 The occurrence of schistosomiasis within African infants and preschool chi